Comparable to TNBC, the job of AR within the administration of estrogen receptor-constructive (ER+) breast cancer is an area of Energetic study. AR is expressed in up to 90% of ER+ tumors and preclinical data indicates that AR expression is linked to resistance to both of those tamoxifen and aromata